Our top pick for
Proto Labs Inc is a metal fabrication business based in the US. Proto Labs shares (PRLB) are listed on the NYSE and all prices are listed in US Dollars. Proto Labs employs 2,408 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$70.82|
|52-week range||$63.81 - $286.57|
|50-day moving average||$70.71|
|200-day moving average||$86.82|
|Wall St. target price||$107.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||5.80%|
|1 month (2021-09-17)||-6.74%|
|3 months (2021-07-16)||-18.06%|
|6 months (2021-04-16)||-34.21%|
|1 year (2020-10-16)||-51.46%|
|2 years (2019-10-18)||-32.03%|
|3 years (2018-10-18)||126.7|
|5 years (2016-10-18)||31.25%|
Valuing Proto Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Proto Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Proto Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Proto Labs shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Proto Labs's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.71. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Proto Labs's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Proto Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $92.6 million.
The EBITDA is a measure of a Proto Labs's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$451.9 million|
|Operating margin TTM||12.57%|
|Gross profit TTM||$217.8 million|
|Return on assets TTM||4.31%|
|Return on equity TTM||5.71%|
|Market capitalisation||$2 billion|
TTM: trailing 12 months
There are currently 2.7 million Proto Labs shares held short by investors – that's known as Proto Labs's "short interest". This figure is 4.6% down from 2.8 million last month.
There are a few different ways that this level of interest in shorting Proto Labs shares can be evaluated.
Proto Labs's "short interest ratio" (SIR) is the quantity of Proto Labs shares currently shorted divided by the average quantity of Proto Labs shares traded daily (recently around 281085.02617801). Proto Labs's SIR currently stands at 9.55. In other words for every 100,000 Proto Labs shares traded daily on the market, roughly 9550 shares are currently held short.
However Proto Labs's short interest can also be evaluated against the total number of Proto Labs shares, or, against the total number of tradable Proto Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Proto Labs's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Proto Labs shares in existence, roughly 100 shares are currently held short) or 0.0972% of the tradable shares (for every 100,000 tradable Proto Labs shares, roughly 97 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Proto Labs.
Find out more about how you can short Proto Labs stock.
We're not expecting Proto Labs to pay a dividend over the next 12 months.
Over the last 12 months, Proto Labs's shares have ranged in value from as little as $63.81 up to $286.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Proto Labs's is 1.6571. This would suggest that Proto Labs's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Proto Labs, Inc. , together with its subsidiaries, operates as an e-commerce driven digital manufacturer of custom prototypes and on-demand production parts in the worldwide. The company offers injection molding; computer numerical control machining; three-dimensional (3D) printing, which include stereolithography, selective laser sintering, direct metal laser sintering, multi jet fusion, polyjet, and carbon DLS processes; and sheet metal fabrication products, including quick-turn and e-commerce-enabled custom sheet metal parts. It serves developers and engineers, who use 3D computer-aided design software to design products across a range of end markets. The company was founded in 1999 and is headquartered in Maple Plain, Minnesota. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.